BB Biotech (BION)

Business description

BION is a Switzerland-domiciled investment company, targeting attractive long-term returns from predominantly mid-/large-cap biotech companies with established product portfolios (sales and earnings) and promising pipeline candidates. It is benchmarked against the NASDAQ Biotech Index, but is managed bottom-up with a concentrated 20-35 stock portfolio.

Double-digit returns with a double-digit discount

Review | Investment Companies | 21/07/2014

BB Biotech AG (BION) is a Swiss-based investment company specialising in the biotechnology sector, with a focus on mid-sized and larger companies that are already generating revenues. Exposure to success stories such as Gilead, whose hepatitis C treatment Sovaldi became a record seller on its introduction earlier this year, has seen the portfolio achieve annualised gains of more than 20% over five years, yet the discount to NAV remains wide, at 20% (double the peer group average excluding BION). A 5% annual distribution policy means BION is the only biotech specialist trust with a yield, equivalent to 4.5% at 16 July.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.CHF3739.5m
Last closeCHF67.500
High / Low (52 weeks)CHF73.4 / CHF54.2
Stock market listingSW, IM
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamInvestment Companies
SectorInvestment Companies

Price performance

%1m3m12m
Actual1.7(2.9)24.3
Relative *0.4(2.4)24.3

* % Relative to local index

Company news

BB Biotech AG

Tue, 08 May 2018 23:37:30 GMT

BB Biotech AG

Fri, 20 Apr 2018 05:03:45 GMT

BB Biotech AG

Thu, 03 May 2018 10:07:30 GMT

BB Biotech AG

Wed, 16 May 2018 11:37:30 GMT

BB Biotech AG

Mon, 14 May 2018 11:23:52 GMT